Nasopharyngeal carcinoma. Recent data;Les carcinomes du nasopharynx: Données actuelles

Pathologie Biologie

Volumn 53, Issue 1, 2005, Pages 45-51

  Boussen, H ^a   Bouaouina, N ^b   Mokni Baizig, N ^a   Gamoudi, A ^a   Chouchane, L ^c   Benna, F ^a   Ladgham, A ^a  

^a SALAH AZAIEZ INSTITUTE   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c Laboratoire d'Immunologie   (Tunisia)

Author keywords

Carcinoma; Carcinome; Chimioth rapie; Epstein Barr; Epstein Barr virus; G ne suppresseur; HLA; Indiff renci ; Marqueur tumoral; Nasopharyngeal; Nasopharynx; Oncogenes; Radioth rapie; S rologie; Undifferentiated; Virus

Indexed keywords

BIOCHEMICAL MARKER; CISPLATIN; CYTOKERATIN 19 FRAGMENT; EARLY ANTIGEN; IMMUNOGLOBULIN A; LATENT MEMBRANE PROTEIN 1; VIRUS CAPSID ANTIGEN;

B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CARCINOGENESIS; CHROMOSOME ABERRATION; EPITHELIUM CELL; EPSTEIN BARR VIRUS; HEAD AND NECK CARCINOMA; HIGH RISK PATIENT; HUMAN; NASOPHARYNX CARCINOMA; OROPHARYNX; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; SOUTHEAST ASIA; SOUTHERN EUROPE; TUMOR CELL; VIRUS CARCINOGENESIS; VIRUS INFECTION;

EID: 11144348674     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2004.01.006     Document Type: Article

References (56)

1. Fandi A., Altun M., Azli N., Arn-iand J.P., Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging and treatment. Semin Oncol. 21:1994;382-397
2. IARC. Cancer in five continents.
3. Bouaouina N., Kabbaj O., Bouzouita K., Boussen H., Ghannem H., Harrabi I., et al. Le cancer du cavum de l'enfant. Cancer radiother. S4:2000;162s
4. Vokes E.E., Liebowitz D.N. Nasopharyngeal carcinoma. Lancet. 350:1997;1087-1091
5. Kieff E. Epstetin-Barr virus and its replication. 3rd edn Fields B.N., Knipe D.M., Howley P.M. Fields virology. 1996;2349-2396 Lippincott-Raven, Philadelphia
6. Tsang N.M., Chang K.P., Lin S.Y., Hao S.P., Tseng C.K., Kuo T.T., et al. Detection of Epstein-Barr virus-derived latent membrane protein-1 gene in various head and neck cancers: is it specific for nasopharyngeal carcinoma? Laryngoscope. 113:2003;1050-1054
7. Dillner J., Kallin B. The Epstein-Barr virus proteins. Adv Cancer Res. 50:1988;95-158
8. Rawlins D.R., Milman G., Hayward S.D., Hayward G.S. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell. 42:1985;859-868
9. Gahn T.A., Schildkraut C.L. The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell. 58:1989;527-535
10. Zeng Y. Seroepidemiolgical studies on nasopharyngeal carcinoma in China. Adv Cancer Res. 43:1985;121-138
11. Tsai S.T., Jin Y.T., Ambinder R.F., Hyaward S.D. Epstein-Barr virus detection in nasopharyngeal tissues of patients with suspected nasopharyngeal carcinoma. Cancer. 82:1998;1449-11443. and
12. characterization of Epstein-Barr virus in clinical specimens. Am J Pathol. 145:1994;239-252
13. Sheng W., Decaussin G., Ligout A., Takada K., Ooka T. Malignant transformation of Epstein-Barr virus-negative Akata cells by introduction of the BARF1 gene carried by Epstein-Barr virus. J Virol. 77:2003;3859-3865
14. Fahraeus R., Rymo L., Rhim J.S., Klein G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature. 345:1990;447-449
15. Decaussin G., Sbih-Lammali F., de Turenne-Tessier M., Bouguermouh A., Ooka T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res. 60:2000;5584-5588
16. Wei M.X., De Turenne-Tessier M., Decaussin G., Benet G., Ooka T. establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus. Oncogene. 14:1997;3073-3081
17. Hui A.B., Lo K.W., Leung S.F., Teo P., Fung M.K., To K.F., et al. Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer. 82:1999;498-503
18. Lo K.W., Kwong J., Hui A.B., Chan S.Y., To K.F., Chan A.S., et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 61:2001;3877-3881
19. Lerman M.I., Minna J.D. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res. 60:2000;6116-6133. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium
20. Croce C.M., Sozzi G., Huebner K. Role of FHIT in human cancer. J Clin Oncol. 17:1999;1618-1624
21. Kwong J., et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8:2002;131-137
22. Wu S., Lay J.D., Chen C.L., Chen J.Y., Liu M.Y., Su I.J. Genomic analysis of Epstein-Barr virus variant in T-cell-lymphoma tissues identical to the distinct strain observed in nasopharuyngeal carcinoma in the Taiwanese population. InJ Cancer. 62:1995;673-677
23. Lam P.K., To E.W., Chan E.S., Liew C.T., Lung I.W., King W.K. In vitro inhibition of head and neck cancer-cell growth by human recombinant interferon-alpha and 13-cis retinoic acid. Br J Biomed Sci. 58:2001;226-229
24. Wong N., Hui A.B., Fan B., Lo K.W., Pang E., Leung S.F., Huang D.P., Johnson P.J. Molecular cytogenetic characterization of nasopharyngeal carcinoma cell lines and xenografts by comparative genomic hybridization and spectral karyotyping. Cancer Genet Cytogenet. 140:2003;124-132
25. Huang D.P., Lo K.W., Van Hasselt C.A., Woo J.K., Choi P.H., Leung S.F., et al. A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res. 54:1994;4003-4006
26. Lo K.W., Huang D.P., Lau K.M. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res. 55:1995;2039-2043
27. Lo K.W., Teo P.M., Hui A.B., To K.F., Tsang Y.S., Chan S.Y., Mak K.F., Lee J.C., Huang D.P. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res. 60:2000;3348-3353
28. Kuramochi M., Fukuhara H., Nobukuni T., Kanbe T., Maruyama T., Ghosh H.P., et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet. 27:2001;427-430
29. Nelson J.B., Chan-Tack K., Hedican S.P., Magnuson S.R., Opgenorth T.J., Bova G.S., et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56:1996;663-668
30. Claudio P.P., Howard C.M., Fu Y., Cinti C., Califano L., Micheli P., Mercer E.W., Caputi M., Giordano A. Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma. Cancer Res. 60:2000;8-12
31. Feng B.J., Huang W., Shugart Y.Y., Lee M.K., Zhang F., Xia J.C., et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet. 31:2002;395-399
32. Jalbout M., Bouaouina N., Gargouri J., Corbex M., Ben Ahmed S., Chouchane L. Polymorphism of the stress protein HSP70-2 is associated with the suceptibility to the nasopharyngeal carcinoma. Cancer Lett. 10:(193):2003;75-81
33. Cho E.Y., Hildesheim A., Chen C.J., Hsu M.M., Chen I.H., Mittl B.F., et al. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiol Biomarkers Prev. 12:2003;1100-1104
34. Goldsmith D.B., West T.M., Morton R. HLA associations with nasopharyngeal carcinoma in Southern Chinese: a meta-analysis. Clin Otolaryngol. 27:2002;61-67
35. Dardari R., Khyatti M., Jouhadi H., Benider A., Ettayebi H., Kahlain A., et al. Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma. Int J Cancer. 92:2001;294-297
36. Mokni-Baizig N., Ayed K., Ben Ayed F., Sassi F., Ladgham A., Belhaj O., et al. Association between HLA-A/-B antigens and DRB1 alleles and nasopharyngeal carcinoma in Tunisia. Oncology. 61:2001;55-58
37. Burt R.D., Vaughan T.L., McKnight B., Davis S., Beckmann A.M., Smith A.G., Nisperos B., Swanson G.M., Berwick M. Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States. Cancer Epidemiol Biomarkers Prev. 5:1996;879-887
38. Sasco A.J. Dépistage des carcinomes indifférenciés du nasopharynx. Bull Cancer. 83:1996;344-351
39. Mai S., Zong Y., Zhang M., Zhong B., Lin S. Detection of Epstein-Barr virus DNA in plasma/serum. A useful indicator for diagnosis of nasopharyngeal carcinoma. Chin Med J. 115:2002;1895-1897
40. Jmel A., Abdennebi M., Boussen H., Gara S., Bendjemana K., Essafer S., et al. Apport du CYFRA 21-1 sérique au diagnostic initial de cancer du nasopharynx en Tunisie. Étude prospective à propos de 41 cas. Bull Cancer. 2004;. (sous presse)
41. Chan K.H., Gu Y.L., Ng F., Ng P.S., Seto W.H., Sham J.S., et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer. 105:2003;706-709
42. Yip T.T., Ngan R.K., Lau W.H., Poon Y.F., Joab I., Cochet C., et al. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer. 74:1994;2414-2424
43. Mebazaa A., Boussen H., Nouira R., Rokbani L., Ben Osman-Dhahri A., Bouaouina N., et al. Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases. J Am Acad Dermatol. 48:2003;530-534
44. Cvitkovic E., Bachouchi M., Boussen H., Busson P., Rousselet G., Mahjoubi R., et al. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J Clin Oncol. 11:1993;2434-2442
45. Law C.K., Foo W., Lau W.H. In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinoma: prognostic homogeneity and proposed refinements. Int J Radiat Oncol Biol Phys. 56:2003;413-426
46. Marks J.E., Bedwinek J.M., Lee F., Purdy J.A., Perez C.A. Dose-response analysis for nasopharyngeal carcinoma: an historical perspective. Cancer. 50:1982;1042-1050
47. Boussen H., Kochbati L., Daoud J., Touati S., Chebbi A., Saadi A., et al. Cancers secondaires après traitement pour carcinome indiffé rencié du cavum en Tunisie. Étude rétrospective à propos de 11 cas. Bull Cancer. 2004;. (Sous presse)
48. Chan A.T., Teo P.M., Johnson P.J. Nasopharyngeal carcinoma. Ann Oncol. 13:2002;1007-1015
49. International Nasopharynx Cancer study Group. VUMCA I trial: preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin-epirubicin-bleomycin) plus radiotherapy vs radiotherapy alone in stage IV(V >N2,M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 36:1996;1005-1012
50. Chua D.T., Sham J.S., Choy D., Lorvidhaya V., Sumitsawan Y., Thongprasert S., Vootiprux V., Cheirsilpa A., Azhar T., Reksodiputro A.H. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy vs radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 83:1998;2270-2283
51. Cheng S.H., Jian J.J., Tsai S.Y., Yen K.L., Chu N.M., Chan K.Y., et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 48:2000;1323-1330
52. Al-Sarraf M., LeBlanc M., Giri P.G., Fu K.K., Cooper J., Vuong T., et al. Chemoradiotherapy vs radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 16:1998;1310-1317
53. Oh J.L., Vokes E.E., Kies M.S., Mittal B.B., Witt M.E., Weichselbaum R.R., Haraf D.J. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 14:2003;564-569
54. Wang C.C. Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx. Techniques and results. Cancer. 63:1989;2461-2467
55. Lin J.C., Chen K.Y., Jan J.S., Hsu C.Y. Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 36:1996;1127-1136
56. Kam M.K., Chau R.M., Suen J., Choi P.H., Teo P.M. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys. 56:2003;145-157